Alberta Investment Management Corp Neurocrine Biosciences Inc Transaction History

Alberta Investment Management Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $7.61 Million - $9.47 Million	-80,895 Reduced 97.71%	1,900 $213,000
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $696,274 - $815,573	7,777 Added 10.37%	82,795 $7.81 Million
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $413,237 - $540,180	-4,391 Reduced 5.53%	75,018 $7.59 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $2.1 Million - $2.5 Million	-19,697 Reduced 19.87%	79,409 $9.48 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $6.19 Million - $7.25 Million	67,244 Added 211.05%	99,106 $10.5 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $12,277 - $16,211	162 Added 0.51%	31,862 $3.11 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $2.3 Million - $3.01 Million	31,700 New	31,700 $2.97 Million

654

96.5M

282K

281K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.4B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Alberta Investment Management Corp, based on Form 13F filings with the SEC.

Stay updated on Alberta Investment Management Corp with notifications on news.